Chemistry:Dusigitumab
From HandWiki
Revision as of 17:59, 16 July 2022 by imported>Scavis (simplify)
Short description: Chemical compound
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | IGF2 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6372H9824N1700O2016S54 |
Molar mass | 144233.81 g·mol−1 |
Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGF2.[1][2] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.[3] Its development has been discontinued.[2]
References
- ↑ "Dusigitumab". Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association. http://www.ama-assn.org/resources/doc/usan/dusigitumab.pdf.
- ↑ 2.0 2.1 "Therapeutic Targeting of the IGF Axis". Cells 8 (8): 895. August 2019. doi:10.3390/cells8080895. PMID 31416218.
- ↑ "Dusigitumab - MedImmune". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800030209.
![]() | Original source: https://en.wikipedia.org/wiki/Dusigitumab.
Read more |